London-based life sciences startup Kiin Bio has successfully raised €1.9 million in an oversubscribed pre-Seed funding round. The round was led by b2venture, with participation from Heartfelt, rule30, and several strategic angel investors. This significant investment will fuel Kiin Bio's growth, enabling them to expand their client base, enhance their AI capabilities, and scale their team.
Kiin Bio's innovative Virtual Scientist Platform, KiinOS, aims to revolutionize the drug discovery process. The platform integrates various tools and data sources to streamline research, from literature review to wet-lab execution. A community edition of the platform is slated for release later this year, further expanding its reach within the scientific community.
The company's AI-native approach tackles the significant challenges of the fragmented and costly drug discovery process. By unifying disparate tools and data, Kiin Bio aims to accelerate research and unlock faster innovation in the pharmaceutical industry. Their existing Frontier Programme already boasts three pilot projects, three commercial partnerships, and a European grant, demonstrating early market traction.
The €1.9 million investment will be instrumental in scaling Kiin Bio's operations and solidifying its position as a leader in AI-driven drug discovery. The company's ambitious vision and strong investor backing position it for significant growth in the rapidly expanding GenAI market for drug discovery.
